Abstract Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the
latest class of antiretrovirals (ARVs) that have become available to treat human …

The integrase strand transfer inhibitor (INSTI)-containing regimens are currently considered
as the first-line treatment of human immunodeficiency virus (HIV) infection. Although …

Abstract Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of
the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) …

The first two integrase strand transfer inhibitors (INSTI s) approved for treatment of patients
infected with human immunodeficiency virus (HIV) were raltegravir and elvitegravir. Both …

The human immunodeficiency virus type-1 (HIV-1) integrase enzyme has recently emerged
as a primary alternative target to block viral replication, and integrase strand transfer …

HIV-1 integrase (IN) is one of three essential enzymes (along with reverse transcriptase and
protease) encoded by the viral pol gene. IN mediates two critical reactions during viral …

HIV drug resistance has been one of the major obstacles to HIV eradication and has
contributed to the need for the constant development of new antiretroviral drugs over the …

Purpose Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV
infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Introduction: HIV-1 integrase strand transfer inhibitors (INSTIs) are a novel class of
antiretroviral drugs with a good safety profile. Several INSTIs have been developed …